Cat. # | Size | Qty. | Price |
---|---|---|---|
18553S | 100 µl |
|
REACTIVITY | H Mk |
SENSITIVITY | Endogenous |
MW (kDa) | 116 |
Source/Isotype | Rabbit IgG |
Product Information
Application | Dilution |
---|---|
Western Blotting | 1:1000 |
Simple Western™ | 1:10 - 1:50 |
For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
NOTE: Please refer to primary antibody product webpage for recommended antibody dilution.
From sample preparation to detection, the reagents you need for your Western Blot are now in one convenient kit: #12957 Western Blotting Application Solutions Kit
NOTE: Prepare solutions with reverse osmosis deionized (RODI) or equivalent grade water.
Load 20 µl onto SDS-PAGE gel (10 cm x 10 cm).
NOTE: Loading of prestained molecular weight markers (#59329, 10 µl/lane) to verify electrotransfer and biotinylated protein ladder (#7727, 10 µl/lane) to determine molecular weights are recommended.
NOTE: Volumes are for 10 cm x 10 cm (100 cm2) of membrane; for different sized membranes, adjust volumes accordingly.
* Avoid repeated exposure to skin.
posted June 2005
revised June 2020
Protocol Id: 10
Human, Monkey
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Leu201 of human caprin1 protein.
Cytoplasmic activation- and proliferation-associated protein 1 (caprin1) is a ubiquitously expressed RNA binding protein (RBP) that plays an important role in cell cycle regulation. Caprin1 is primarily localized to the cytoplasm and interacts with mRNA through its C-terminal RGG motifs (1). Caprin1 interacts with a variety of mRNA involved in cell cycle regulation, including c-Myc and cyclin D2 (1,2). Additionally, knockout of caprin1 reduces cell proliferation by delaying the transition from the G1 to the S phase of the cell cycle (3). Misregulation of the cell cycle suggests a potential tumorigenic role for caprin1, and its overexpression has been found to promote tumor growth and metastasis in osteosarcoma through interaction with Cyr61 (4). Caprin1 is also known to phase separate and localize to specific RNA granules called stress granules (SGs). SGs are cytoplasmic mRNA-protein condensates that are formed in response to cellular stressors, such as oxidative stress, ultraviolet radiation, and viral infection (5). Caprin1 is a key mediator of SG formation along with the proteins G3BP1 and USP10 (6,7). SG formation is a reversible process under normal physiological conditions, but chronic stress can disrupt SG dissolution and lead to the aggregation of proteins linked to various neurodegenerative diseases (8). Indeed, a missense P512L mutation in the CAPRIN1 gene has been linked to early-onset ataxia, potentially through a gain-of-function mechanism that promotes protein aggregation (9).
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.